Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Liraglutide has pleiotropic effects favouring cardiovascular and renal risks.

The researchers performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes.

Who Took Part

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

HbA1c, body weight, systolic blood pressure (SBP), low density lipoprotein (LDL)-cholesterol, urine albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) were measured at baseline and after 26 weeks of liraglutide/placebo treatment: "Good responders" had a change within the best quartile.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

The comparison arm used a placebo, so changes seen with Liraglutide could be set against what happens without it.

The timeline in the abstract includes 26 weeks.

What Was Measured

The researchers performed secondary analysis of the LIRA-RENAL trial (n = 279) in type 2 diabetes.

PubMed files the paper under topics including Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glomerular Filtration Rate, Glycated Hemoglobin, Individuality, Liraglutide and Renal Insufficiency, Chronic.

The authors tagged it with the keywords diabetic nephropathy and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide over 26 weeks.

The publication is from 2019 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Liraglutide compound page.